anubhai angaldas Securities Pvt. Ltd. Member: BSE - NSE - CDSL

Technology . Transparency . Trust

MARKET

Hot Pursuit
Zydus Lifesciences gains after getting tentative approval for dyskinesia drug
04-Oct-2022 14:50

Amantadine is indicated for the treatment of dyskinesia (sudden uncontrolled movements) in patients with Parkinson's disease who are treated with levodopa therapy, with or without dopaminergic medicines.

The pharmaceutical company said that the drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

According to IQVIA MAT August 2022 data, Amantadine Extended-Release Capsules had annual sales of $2.7 million in the United States.

The group now has 325 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22.

Powered by Capital Market - Live News

Attention Investor
As per CDSL communiqué Kindly update your Email ID, Mobile Number & Income Range in CDSL demat Account on or before 31st May 2021, Non Compliance Account will be INACTIVE after 31st May 2021. | Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors.  | "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." | "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."    Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of Investors.